ACTRN12606000033549
Recruiting
Not Applicable
A trial of Therapeutic Drug Monitoring (TDM) in methadone treatment
The Langton Centre0 sites90 target enrollmentJanuary 25, 2006
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Opiod dependence
- Sponsor
- The Langton Centre
- Enrollment
- 90
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Agree to and be capable of signing an informed consent form.In treatment at least 2 monthsOn a stable methadone dose for at least 4 weeksOn a methadone dose greater than or equal to 50mg/dayUse heroin 4 times or more in the last monthCurrent methadone prescriber consents to subject's participation in the research.
Exclusion Criteria
- •Considered unwilling, unable or unlikely to comply with the study protocolPregnant or breast feedingUsing drugs and dietary components known to interact with methadone pharmacokinetics (including antipsychotics, fluvoxamine, St John's Wort, Grapefruit juice)Unstable medical conditions (liver disease with jaundico/ascites/encephalopathy, structural heart disease, psychosis.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Assessment of Memantine Drug Levels in Blood Among Indian Patients with Brain Metastases Treated with Radiation TherapyHealth Condition 1: C719- Malignant neoplasm of brain, unspecifiedCTRI/2024/04/066217Amrita School of Pharmacy
Active, not recruiting
Not Applicable
Effectiveness of theraPeutic drug mOnitoring (TDM) on mucosal and transmural healing in pediatric patients with moderate to severe luminal CroHn’s disease newly receiving Remsima(infliximab): EPOCH studyDiseases of the digestive systemKCT0005190Samsung Medical Center116
Recruiting
Not Applicable
Influence of therapeutic drug monitoring (TDM) on the tolerability and efficacy of 5-FU-containing chemotherapy in patients with colorectal carcinoma in the colorectal center at St.-Franziskus-Hospital Münster: a prospective, monocentric observational study.C18Malignant neoplasm of colonDRKS00026926St. Franziskus-Hospital GmbH50
Withdrawn
Not Applicable
se of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19COVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620000447954Royal Brisbane & Women's Hospital150
Active, not recruiting
Phase 1
Measurement of the blood concentration of the antibiotic piperacillin and individual drug dosage in patients with febrile neutropenia after chemotherapyPatients with febrile neutropenia after myelo-suppressive chemotherapy treated with piperacillin/tazobactamTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2016-002388-33-DEFriedrich-Schiller-University Jena208